Descripción del proyecto
Una nueva vacuna protege la salud y la productividad del ganado
La vacunación representa la estrategia más eficaz para proteger al ganado contra múltiples enfermedades, lo que minimiza el uso de antibióticos. La diarrea vírica bovina (DVB, o BVD por sus siglas en inglés) es una enfermedad endémica del ganado vacuno provocada por el virus de la DVB (VDVB). En la actualidad, no existen programas de erradicación o control que eliminen la necesidad de utilizar vacunas. El proyecto BoVLP-BVD, financiado con fondos europeos, ha diseñado una vacuna nueva contra el VDVB basada en una tecnología patentada de partículas similivíricas. Sus investigadores llevarán a cabo las actividades preceptivas para la fabricación a escala comercial y la evaluación de la seguridad y la eficacia «in vivo» de la vacuna. El VDVB reduce de manera significativa la productividad y la reproducción de la cabaña ganadera, lo que acarrea importantes pérdidas económicas, por lo que la vacuna de BoVLP-BVD ayudará a prevenir esta enfermedad.
Objetivo
In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime. Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals.
Aquilón CyL, a leading biotech company, has developed new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. Aquilón has demonstrated the technical, commercial and regulatory feasibility by the SME instrument phase 1 project (nº 774994). After developing the vaccine to TRL6 stage (pre-industrial prototype with positive activity data), Aquilón will develop one vaccine to TRL8 stage, demonstrating the commercial-scale manufacturing and in-vivo safety, efficacy and DIVA attributes in the target species. This vaccine candidate will be licensed to one or more veterinarian pharmaceutical company that will complete the final field studies required for commercialisation. Our business projections, based on agreements with Development milestones and commercial royalties, show potential for a 5X investment multiplier with a 25% internal rate of return.
Ámbito científico
- natural sciencesbiological sciencesmicrobiologyvirology
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- agricultural sciencesanimal and dairy sciencedomestic animalsanimal husbandry
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-2
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
24000 LEON
España
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.